GTBP
GT Biopharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GTBP
Gt Biopharma, Inc.
A clinical stage biopharmaceutical company that develops immuno-therapeutic products
--
--
GT Biopharma, Inc., was incorporated in California in 1965. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products with a proprietary tri-specific killer adapter fusion protein immune cell adapter technology platform. TriKE can be designed to target any number of tumor antigens in hematological malignancies or solid tumors and does not require patient-specific customization.
Company Financials
EPS
GTBP has released its 2023 Q3 earnings. EPS was reported at -0.06, versus the expected -0.1, beating expectations. The chart below visualizes how GTBP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
